Pharmaceutical News

RSS

Cannabis compound d-limonene reduces anxiety-inducing effects of THC

A Johns Hopkins Medicine-led research team has added to evidence that a chemical found naturally in cannabis (also known as marijuana) can -; in the right amounts -; lessen the anxiety-inducing effects of tetrahydrocannabinol (THC), the primary psychoactive sister chemical found in cannabis.

12 Apr 2024

Is psilocybin safe for treating depression and anxiety?

A study in JAMA Network Open examined the acute adverse effects of therapeutic doses of psilocybin for treating depression and anxiety, focusing on its safety profile by assessing the occurrence of immediate side effects like headache, nausea, and elevated blood pressure among others.

12 Apr 2024

Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook

Study finds that receiving an annual COVID-19 vaccine is clinically and economically beneficial for individuals, regardless of insurance status, offering savings by reducing the likelihood of infection and its associated costs.

11 Apr 2024

Popular diabetes drugs not linked to thyroid cancer risk, study finds

SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths

study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.

9 Apr 2024

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial

A study in The New England Journal of Medicine evaluates the combination of nirmatrelvir and ritonavir against COVID-19, finding it does not significantly reduce symptom duration in vaccinated or unvaccinated adult outpatients.

8 Apr 2024

DEPOSITION trial evaluates the use of topical tranexamic acid during heart surgery

Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically rather than intravenously did not meet its primary endpoint of reducing seizures and was stopped early due to an increased risk of bleeding events, according to research presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.

8 Apr 2024

Study: Empagliflozin shows mixed results in heart attack patients

Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Pioneering vaccine strategy promises to outmaneuver antimicrobial resistance

Study introduces Reverse Vaccine Development as a strategic approach to identify correlates of protection early in vaccine development against antimicrobial-resistant pathogens, aiming to mitigate risks such as significant phase-III clinical trial failures.

7 Apr 2024

Study questions routine use of beta blockers after heart attack

Taking beta blockers after a heart attack did not significantly reduce the risk of death or a second heart attack among people with normal heart pumping ability, as indicated by an ejection fraction of 50% or higher, according to a study presented at the American College of Cardiology's Annual Scientific Session.

7 Apr 2024

Study shows promise of zilebesiran injection in reducing systolic blood pressure

A single subcutaneous injection of the investigational drug zilebesiran, when added to existing treatment with a standard antihypertensive medication, reduced systolic blood pressure by between 4 to 12 mmHg on average at three months in patients whose blood pressure had remained uncontrolled despite compliance with their medication regimen, according to a study presented at the American College of Cardiology's Annual Scientific Session.

7 Apr 2024